14,760 Shares in BioNTech SE (NASDAQ:BNTX) Purchased by Cinctive Capital Management LP

Cinctive Capital Management LP purchased a new stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 14,760 shares of the company's stock, valued at approximately $1,682,000.

Several other institutional investors have also recently bought and sold shares of the business. Daiwa Securities Group Inc. increased its stake in shares of BioNTech by 7.1% in the fourth quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock valued at $221,000 after buying an additional 128 shares in the last quarter. Bank of New York Mellon Corp increased its position in BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock valued at $419,000 after acquiring an additional 150 shares in the last quarter. Midwest Professional Planners LTD. raised its stake in shares of BioNTech by 5.8% in the fourth quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company's stock worth $462,000 after acquiring an additional 222 shares during the last quarter. Perigon Wealth Management LLC lifted its position in shares of BioNTech by 3.9% during the fourth quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company's stock worth $666,000 after purchasing an additional 224 shares in the last quarter. Finally, Atomi Financial Group Inc. grew its stake in shares of BioNTech by 6.7% during the fourth quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company's stock valued at $414,000 after purchasing an additional 229 shares during the last quarter. Institutional investors own 15.52% of the company's stock.

Remove Ads

Analyst Ratings Changes

BNTX has been the topic of several research reports. BMO Capital Markets upped their price objective on BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Citigroup initiated coverage on BioNTech in a report on Thursday, March 13th. They issued a "buy" rating and a $145.00 price target on the stock. Wells Fargo & Company assumed coverage on BioNTech in a research report on Wednesday, December 11th. They issued an "overweight" rating and a $170.00 price objective for the company. Canaccord Genuity Group restated a "buy" rating and set a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. Finally, HC Wainwright lowered their price target on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, BioNTech has a consensus rating of "Moderate Buy" and a consensus price target of $143.44.

BioNTech Stock Up 8.6 %

BNTX stock traded up $7.49 during mid-day trading on Wednesday, hitting $94.14. 1,569,494 shares of the company were exchanged, compared to its average volume of 849,540. The firm has a market cap of $22.59 billion, a P/E ratio of -44.83 and a beta of 1.07. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm's 50 day simple moving average is $105.58 and its 200 day simple moving average is $111.98.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company's revenue for the quarter was down 19.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.90 EPS. On average, sell-side analysts predict that BioNTech SE will post -3.88 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.